<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04197622</url>
  </required_header>
  <id_info>
    <org_study_id>IMIMFTCL/HCTZ</org_study_id>
    <nct_id>NCT04197622</nct_id>
  </id_info>
  <brief_title>Generation of Biological Samples Positive to Hydrochlorothiazide for Anti-doping Control</brief_title>
  <acronym>HCTZ</acronym>
  <official_title>Generation of Biological Samples Positive to Hydrochlorothiazide for Anti-doping Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Parc de Salut Mar</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Parc de Salut Mar</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      Hydrochlorothiazide is a diuretic that inhibits the reabsorption of sodium and chloride in&#xD;
      the renal tubules, thus increasing the excretion of water.&#xD;
&#xD;
      The use of hydrochlorothiazide in athletes is prohibited by the World Anti-Doping Agency. Its&#xD;
      fraudulent administration can lead to significant acute weight losses (body water reduction)&#xD;
      and can mask the use of other doping substances, since it increases the urine volume and&#xD;
      alters its pH (false negatives).&#xD;
&#xD;
      The main degradation product of hydrochlorothiazide is&#xD;
      4-amino-6-chloro-1,3-benzenedisulfonamide (ACB). ACB is detectable in urine for a longer time&#xD;
      and in a greater concentration than hydrochlorothiazide. This suggests that ACB may be an&#xD;
      important marker for the detection of hydrochlorothiazide doping.&#xD;
&#xD;
      Hypothesis:&#xD;
&#xD;
      The oral administration of 12,5 mg of hydrochlorothiazide in healthy subjects allows&#xD;
      generating detectable concentrations of the drug in urine. Positive urine samples will enable&#xD;
      to identify analytical strategies for doping control.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      Primary objective: To measure the concentrations of hydrochlorothiazide in urine for&#xD;
      anti-doping control samples.&#xD;
&#xD;
      Secondary objectives: To identify hydrochlorothiazide metabolites in urine. To explore the&#xD;
      time window in which the drug or its metabolites can be detected in urine after&#xD;
      administration. To assess safety and tolerability of the drug used.&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      Phase I, open, non-randomized clinical trial, with a treatment condition&#xD;
      (hydrochlorothiazide) administered in a single oral dose to 3 subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 5, 2019</start_date>
  <completion_date type="Actual">March 21, 2019</completion_date>
  <primary_completion_date type="Actual">March 21, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urine concentration of hydrochlorothiazide</measure>
    <time_frame>0-4 hours post-administration</time_frame>
    <description>Concentration of hydrochlorothiazide in fraction-1 urine samples</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine concentration of hydrochlorothiazide</measure>
    <time_frame>4-8 hours post-administration</time_frame>
    <description>Concentration of hydrochlorothiazide in fraction-2 urine samples</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine concentration of hydrochlorothiazide</measure>
    <time_frame>8-12 hours post-administration</time_frame>
    <description>Concentration of hydrochlorothiazide in fraction-3 urine samples</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine concentration of hydrochlorothiazide</measure>
    <time_frame>12-24 hours post-administration</time_frame>
    <description>Concentration of hydrochlorothiazide in fraction-4 urine samples</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine concentration of hydrochlorothiazide</measure>
    <time_frame>24-36 hours post-administration</time_frame>
    <description>Concentration of hydrochlorothiazide in fraction-5 urine samples</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine concentration of hydrochlorothiazide</measure>
    <time_frame>36-48 hours post-administration</time_frame>
    <description>Concentration of hydrochlorothiazide in fraction-6 urine samples</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urine concentration of hydrochlorothiazide metabolites</measure>
    <time_frame>0-4 hours post-administration</time_frame>
    <description>Concentration of hydrochlorothiazide metabolites (ACB and others) in fraction-1 urine samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine concentration of hydrochlorothiazide metabolites</measure>
    <time_frame>4-8 hours post-administration</time_frame>
    <description>Concentration of hydrochlorothiazide metabolites (ACB and others) in fraction-2 urine samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine concentration of hydrochlorothiazide metabolites</measure>
    <time_frame>8-12 hours post-administration</time_frame>
    <description>Concentration of hydrochlorothiazide metabolites (ACB and others) in fraction-3 urine samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine concentration of hydrochlorothiazide metabolites</measure>
    <time_frame>12-24 hours post-administration</time_frame>
    <description>Concentration of hydrochlorothiazide metabolites (ACB and others) in fraction-4 urine samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine concentration of hydrochlorothiazide metabolites</measure>
    <time_frame>24-36 hours post-administration</time_frame>
    <description>Concentration of hydrochlorothiazide metabolites (ACB and others) in fraction-5 urine samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine concentration of hydrochlorothiazide metabolites</measure>
    <time_frame>36-48 hours post-administration</time_frame>
    <description>Concentration of hydrochlorothiazide metabolites (ACB and others) in fraction-6 urine samples</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Hydrochlorothiazide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receive a single-dose treatment.Urine samples will be collected after administration (6 fractions: 0-4, 4-8, 8-12, 12-24, 24-36, 36-48 hours post-administration).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrochlorothiazide</intervention_name>
    <description>12,5 mg of hydrochlorothiazide (1/2 tablet of 25 mg) administered orally in a single dose.</description>
    <arm_group_label>Hydrochlorothiazide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male volunteers aged between 18 and 45 years.&#xD;
&#xD;
          -  Able to understand and accept the trial procedures and able to sign an informed&#xD;
             consent.&#xD;
&#xD;
          -  History and physical examination that demonstrate not presenting organic or&#xD;
             psychiatric disorders.&#xD;
&#xD;
          -  ECG, blood and urine tests performed at screening should be within normal limits.&#xD;
             Minor or punctual variations of these limits of normality are admitted if, in the&#xD;
             opinion of the Principal Investigator, they have no clinical significance, do not pose&#xD;
             a risk to the subject and do not interfere with the evaluation of the product in&#xD;
             study. These variations and their non-relevance will be justified in writing&#xD;
             specifically.&#xD;
&#xD;
          -  Body mass index (weight/size^2) between 19 and 26 kg/m2, and weight between 50 and 90&#xD;
             kg. Subjects with BMI &gt;26 kg/m2 may be included at the discretion of the Principal&#xD;
             Investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Failure to meet the inclusion criteria.&#xD;
&#xD;
          -  History of allergy, idiosyncrasy, hypersensitivity or adverse reactions to the active&#xD;
             substance or any of the excipients. History of serious adverse reactions to other&#xD;
             medications.&#xD;
&#xD;
          -  Subjects with contraindications to treatment with the study drug (according to Summary&#xD;
             of Product Characteristics).&#xD;
&#xD;
          -  Background or clinical evidence of psychiatric disorders, alcoholism, regular&#xD;
             consumption of psychoactive drugs, drug abuse or addiction to other substances (except&#xD;
             for nicotine). Smokers of more than 5 cigarettes/day will be excluded.&#xD;
&#xD;
          -  Having participated in another clinical trial with medication in the three months&#xD;
             prior to the start of the study.&#xD;
&#xD;
          -  Having donated blood during the month prior to the start of the study.&#xD;
&#xD;
          -  Having suffered an organic disease or major surgery in the three months prior to the&#xD;
             start of the study.&#xD;
&#xD;
          -  Background or clinical evidence of cardiovascular, respiratory, renal, hepatic,&#xD;
             endocrine, gastrointestinal, hematological, neurological, dermatological or other&#xD;
             acute or chronic diseases that, in the opinion of the Principal Investigator or the&#xD;
             collaborators designated by him, may pose a risk to the subjects, may interfere with&#xD;
             the objectives of the study or may alter the pharmacokinetics of the drug.&#xD;
&#xD;
          -  Have taken medication regularly in the month prior to the study sessions, with the&#xD;
             exception of vitamins, herbal remedies or dietary supplements that, in the opinion of&#xD;
             the Principal Investigator or the collaborators designated by him, do not pose a risk&#xD;
             to the subjects and do not interfere with the objectives of the study. Treatment with&#xD;
             single doses of symptomatic medication in the week prior to the study sessions will&#xD;
             not be exclusive if it is assumed that medication has been completely eliminated on&#xD;
             the day of the experimental session.&#xD;
&#xD;
          -  Consumption of more than 15 g of alcohol per day.&#xD;
&#xD;
          -  Consumers of more than 3 coffees, teas, cola drinks and/or other stimulant drinks&#xD;
             (xanthines) per day in the month prior to the start of the study.&#xD;
&#xD;
          -  Being unable to understand the nature of the trial and the procedures requested to&#xD;
             follow.&#xD;
&#xD;
          -  Positive serology for hepatitis B, C or HIV.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rafael de la Torre Fornell, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>IMIM (Hospital del Mar Medical Research Institute)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IMIM (Hospital del Mar Medical Research Institute)</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 11, 2019</study_first_submitted>
  <study_first_submitted_qc>December 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2019</study_first_posted>
  <last_update_submitted>December 11, 2019</last_update_submitted>
  <last_update_submitted_qc>December 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hydrochlorothiazide</keyword>
  <keyword>Anti-doping control</keyword>
  <keyword>Athletic performance</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrochlorothiazide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

